EUVIMEDEUVIMED entdecken
Crossref

Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network

S Russo, I Capodanno iD, M Tiribelli iD, M C Miggiano iD, D Cattaneo iD, F Cavazzini, S Leonetti Crescenzi, E Scalzulli, A Bernardelli, L Luciano iD, O Mulas iD, G Loglisci und 31 weitere

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von S Russo und 42 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section, AOU Policlinico G. Martino, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Diabetes Mellitus. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limited data are available regarding patients with newly diagnosed chronic myeloid leukemia (CML) and concomitant diabetes mellitus (DM). Hence, we retrospectively analyzed 2149 patients with newly diagnosed chronic phase (CP) CML to compare clinical characteristics, choice of frontline therapy, early adverse events, and molecular responses between patients with or without DM. Among this cohort of 2149 patients, 241 patients (11.2%) had DM at CML diagnosis. Diabetic patients were older (median age 69.6 vs. 58.2 years, p < 0.001), showed a higher Sokal/ELTS risk and had more comorbidities, resulting in more frequent polypharmacy. Imatinib was frequently selected as first‐line treatment in diabetic patients (71% vs. 53%, p < 0.001), whereas nilotinib was more common in nondiabetics (6.2% vs. 31.9%). Discontinuation by the 12th month occurred in 24.2% of diabetic patients versus 19.4% of nondiabetics ( p = 0.031), mainly for hematologic toxicity. Diabetic patients showed a lower incidence of major molecular response (MMR) at the 12th month (55.9% vs. 68.1%, p = 0.002). Among diabetic patients, a trend toward better molecular responses was observed in patients receiving metformin ( p = 0.068). In conclusion, DM represents a clinically meaningful comorbidity in newly diagnosed CML‐CP, and seems to define a subgroup with distinct features, influencing both treatment decisions and early outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDiabetes MellitusHumansFemaleMaleMiddle AgedAgedItalyTreatment OutcomeRetrospective StudiesAged, 80 and overAdultComorbidityImatinib Mesylate

Stichwörter der Autor:innen

CML therapychronic myeloid leukemiadiabetestyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsImatinib Mesylate

Autor:innen und Institutionen

  • Hematology Section, AOU Policlinico G. Martino, University of Messina, Messina, Italy.
  • Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Division of Hematology and BMT, Department of Medical Area, University of Udine, Udine, Italy.
  • Hematology Department, San Bortolo Hospital, Vicenza, Italy.
  • Hematology Division, Foundation IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milan, Italy.
  • Hematology Unit, University of Ferrara, Ferrara, Italy.

ORCID-Profile: I Capodanno, M Tiribelli, M C Miggiano, D Cattaneo, L Luciano, O Mulas, I Attolico, G Binotto, P Sportoletti, M Fazio, M Bocchia, C Fava, S Galimberti, I Vincelli, G Caocci, M Bonifacio, A Iurlo, A Allegra, G Saglio, G Specchia, M Breccia, F Stagno, R Latagliata

Zitieren

APA

Russo, S., Capodanno, I., Tiribelli, M., Miggiano, M. C., Cattaneo, D., Cavazzini, F., Leonetti Crescenzi, S., Scalzulli, E., Bernardelli, A., Luciano, L., Mulas, O., Loglisci, G., Elena, C., Morelli, G. L., Attolico, I., Binotto, G., Crisà, E., Sportoletti, P., Di Veroli, A., …, & Latagliata, R. (2026). Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network. European Journal of Haematology. https://doi.org/10.1111/ejh.70268

Vancouver

Russo S, Capodanno I, Tiribelli M, Miggiano MC, Cattaneo D, Cavazzini F, et al. Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network. European Journal of Haematology. 2026. doi:10.1111/ejh.70268

BibTeX
@article{Russo2026,
  author = {Russo, S and Capodanno, I and Tiribelli, M and Miggiano, M C and Cattaneo, D and Cavazzini, F and Leonetti Crescenzi, S and Scalzulli, E and Bernardelli, A and Luciano, L and Mulas, O and Loglisci, G and Elena, C and Morelli, G L and Attolico, I and Binotto, G and Crisà, E and Sportoletti, P and Di Veroli, A and Scortechini, A R and Leporace, A P and Basile, M and Crugnola, M and Fazio, M and Murgano, P and Rapezzi, D and Luzi, D and Bocchia, M and Fava, C and Malato, A and Galimberti, S and Vincelli, I and Trawinska, M and Pizzuti, M and Caocci, G and Bonifacio, M and Iurlo, A and Allegra, A and Saglio, G and Specchia, G and Breccia, M and Stagno, F and Latagliata, R},
  title = {Diabetic Patients With Newly Diagnosed Chronic Myeloid Leukemia: TKI Choice and Early Adverse Events. A Real‐Life Survey Within the Italian Chronic Myeloid Leukemia Network},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70268}
}
Kostenlos starten →